GAMMA Investing LLC Acquires 305 Shares of IQVIA Holdings Inc. (NYSE:IQV)

GAMMA Investing LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 27.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,406 shares of the medical research company’s stock after acquiring an additional 305 shares during the period. GAMMA Investing LLC’s holdings in IQVIA were worth $276,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter worth about $27,000. Park Place Capital Corp acquired a new position in IQVIA in the 3rd quarter valued at approximately $28,000. Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $29,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $202.63 on Wednesday. The stock has a market cap of $36.78 billion, a price-to-earnings ratio of 26.59, a P/E/G ratio of 2.05 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s 50-day simple moving average is $202.22 and its 200 day simple moving average is $221.94.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IQV. The Goldman Sachs Group decreased their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Truist Financial lowered their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.